GREENPLY.NSE

Greenply Industries Ltd.

In this briefing: Avenue Supermarts Ltd - Store Additions Support Growth; LFL Remains Weak MAS Financial Services Ltd - Building a Durable Compounding Franchise Kotak Mahindra Bank Ltd. - Fee Growth and Operating Leverage to Offset Margin Pressure Equitas Small Finance Bank Ltd. - Normalising Credit Costs and Lower Cost Ratios... Greenply Industries Ltd - Good Quarter; Volume Led Growth with Margin Protection 1. Avenue Supermarts Ltd - Store Additions Support Growth; LFL Remains Weak Steady Growth with Stable Operations: The company reported revenue of Rs 17,684 Cr in Q4FY26, reflecting 19% YoY growth. Mature stores (two years and older) delivered growth of 10.8% during the quarter, while full-year LFL growth stood at 8.1%. The company added 58 stores in Q4, taking the total store count to 500. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2.

In this briefing: Equitas Small Finance Bank Ltd. - Normalising Credit Costs and Lower Cost Ratios... Greenply Industries Ltd - Good Quarter; Volume Led Growth with Margin Protection Asian Equities: Nascent Revival in FII Flows in April, but a Long Way to Go Bajaj Finserv (BJFIN IN) Vs. Bajaj Finance (BAF IN): Holding Company Spread Signals 6% Opportunity Bajaj Finance: FY26 Ends Strong 1. Equitas Small Finance Bank Ltd. - Normalising Credit Costs and Lower Cost Ratios... Asset quality Improvement Unserway; West Asia Conflict Impact Limited: EQSFB’s asset quality trends across other segments, particularly MFI, have been improving over the past few quarters and are expected to remain comfortable going forward. While the impact of the West Asia conflict on asset quality remains uncertain, early warning indicators are not expected to reflect any direct stress. So far, Apr’26 slippages have not shown signs of deterioration. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: Equitas Small Finance Bank Ltd. - Normalising Credit Costs and Lower Cost Ratios... Greenply Industries Ltd - Good Quarter; Volume Led Growth with Margin Protection Asian Equities: Nascent Revival in FII Flows in April, but a Long Way to Go Bajaj Finserv (BJFIN IN) Vs. Bajaj Finance (BAF IN): Holding Company Spread Signals 6% Opportunity Bajaj Finance: FY26 Ends Strong 1. Equitas Small Finance Bank Ltd. - Normalising Credit Costs and Lower Cost Ratios... Asset quality Improvement Unserway; West Asia Conflict Impact Limited: EQSFB’s asset quality trends across other segments, particularly MFI, have been improving over the past few quarters and are expected to remain comfortable going forward. While the impact of the West Asia conflict on asset quality remains uncertain, early warning indicators are not expected to reflect any direct stress. So far, Apr’26 slippages have not shown signs of deterioration. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: Greenply Industries Ltd - Good Quarter; Volume Led Growth with Margin Protection Asian Equities: Nascent Revival in FII Flows in April, but a Long Way to Go Bajaj Finserv (BJFIN IN) Vs. Bajaj Finance (BAF IN): Holding Company Spread Signals 6% Opportunity Bajaj Finance: FY26 Ends Strong Uneven Fallout of Middle East Conflict on Emerging Markets, but Asia More Vulnerable to Stagflation 1. Greenply Industries Ltd - Good Quarter; Volume Led Growth with Margin Protection Structural Margin Improvement: Greenply has demonstrated a clear shift towards sustainable profitability, with Q4 margins likely becoming the new baseline. MDF margins are supported by operating leverage, while plywood margins are improving due to process innovation and a better product mix. The introduction of advanced manufacturing technology is expected to enhance quality and reduce costs, especially in H2FY27. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: Greenply Industries Ltd - Good Quarter; Volume Led Growth with Margin Protection Asian Equities: Nascent Revival in FII Flows in April, but a Long Way to Go Bajaj Finserv (BJFIN IN) Vs. Bajaj Finance (BAF IN): Holding Company Spread Signals 6% Opportunity Bajaj Finance: FY26 Ends Strong Uneven Fallout of Middle East Conflict on Emerging Markets, but Asia More Vulnerable to Stagflation 1. Greenply Industries Ltd - Good Quarter; Volume Led Growth with Margin Protection Structural Margin Improvement: Greenply has demonstrated a clear shift towards sustainable profitability, with Q4 margins likely becoming the new baseline. MDF margins are supported by operating leverage, while plywood margins are improving due to process innovation and a better product mix. The introduction of advanced manufacturing technology is expected to enhance quality and reduce costs, especially in H2FY27. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: Exencial Indutry Tiding Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate Axis PUNCH: Greenply Industries Ltd - 17th February, 2026 1. Exencial Indutry Tiding Bajaj Hindusthan Sugar's sales decline by 6.7% in December 2025 quarter Man-Made filaments & fibres industry's sales grow by 15.2% in December 2025 quarter Personal & home care products industry's sales grow by 5.4% in December 2025 quarter 2. Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Indo-MIM Ltd (1666551D IN) (IML) is looking to raise about US$750m in its upcoming India IPO. IML provides end-to-end solutions for the manufacture of precision engineering components using metal injection molding technology. Its capabilities include mold designing and tooling, coupled with finishing and assembly operations.

In this briefing: Exencial Indutry Tiding Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate Axis PUNCH: Greenply Industries Ltd - 17th February, 2026 1. Exencial Indutry Tiding Bajaj Hindusthan Sugar's sales decline by 6.7% in December 2025 quarter Man-Made filaments & fibres industry's sales grow by 15.2% in December 2025 quarter Personal & home care products industry's sales grow by 5.4% in December 2025 quarter 2. Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Indo-MIM Ltd (1666551D IN) (IML) is looking to raise about US$750m in its upcoming India IPO. IML provides end-to-end solutions for the manufacture of precision engineering components using metal injection molding technology. Its capabilities include mold designing and tooling, coupled with finishing and assembly operations.

In this briefing: Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate Axis PUNCH: Greenply Industries Ltd - 17th February, 2026 Ahluwalia Contracts India Ltd - Misses Estimates on Slower Execution; Retain BUY 1. Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Indo-MIM Ltd (1666551D IN) (IML) is looking to raise about US$750m in its upcoming India IPO. IML provides end-to-end solutions for the manufacture of precision engineering components using metal injection molding technology. Its capabilities include mold designing and tooling, coupled with finishing and assembly operations. In this note, we talk about the positive aspects about the company’s historical performance. 2. HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts IPCA Laboratories: EBITDA growth of 22% YoY was driven by 7% YoY sales growth (India grew 12% YoY), higher GM (+226 bps YoY at 72.5%), and cost controls (staff/SG&A +10%/+4% YoY), causing the margin to expand to 22.7% (+284 bps YoY) IPCA expects (1) overall business to see 10-11% growth in the near term (IPCA standalone growth at 10-12% and Unichem business at 8-9%) (2) India business to outperform IPM growth in the next few years, led by sustained momentum in key therapies (pain, CVS, anti-diabetics, CNS, and derma), looking to in-licensing Semaglutide to participate in India GLP-1 market Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate Axis PUNCH: Greenply Industries Ltd - 17th February, 2026 Ahluwalia Contracts India Ltd - Misses Estimates on Slower Execution; Retain BUY 1. Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Indo-MIM Ltd (1666551D IN) (IML) is looking to raise about US$750m in its upcoming India IPO. IML provides end-to-end solutions for the manufacture of precision engineering components using metal injection molding technology. Its capabilities include mold designing and tooling, coupled with finishing and assembly operations. In this note, we talk about the positive aspects about the company’s historical performance. 2. HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts IPCA Laboratories: EBITDA growth of 22% YoY was driven by 7% YoY sales growth (India grew 12% YoY), higher GM (+226 bps YoY at 72.5%), and cost controls (staff/SG&A +10%/+4% YoY), causing the margin to expand to 22.7% (+284 bps YoY) IPCA expects (1) overall business to see 10-11% growth in the near term (IPCA standalone growth at 10-12% and Unichem business at 8-9%) (2) India business to outperform IPM growth in the next few years, led by sustained momentum in key therapies (pain, CVS, anti-diabetics, CNS, and derma), looking to in-licensing Semaglutide to participate in India GLP-1 market Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.